Answers are grounded in this paper and cite their sources.
To clarify whether Pam3CSK4, a TLR2 agonist, induces the differentiation of osteoclasts, we investigated the osteoclastogenesis and gene expression induced by Pam3CSK4 in RAW264.7 monocyte/macrophage cells. We found that 1 μg/ml Pam3CSK4 induced osteoclastogenesis without adding RANKL exogenously, whereas 1 μg/ml LPS (Re mutant), a ligand for TLR4, failed to produce osteoclasts in RAW 264.7 cells. The number of TRAP-positive multinuclear cells in the Pam3CSK4 group (156.2 +/− 26.5 cells/well) was significantly (p<0.01) less than that of 100 ng/ml RANKL (196.5 +/− 32.0 cells/well), which was a positive control. Quantitative real-time RT-PCR analysis showed that i) the gene expression levels of TRAP, cathepsin K and matrix metalloproteinase 9, which are osteoclast differentiation markers, were upregulated (p<0.01) by both RANKL and Pam3CSK4, whereas LPS did not increase gene expression of TRAP or cathepsin K, ii) the expression level of RANK was decreased significantly (p<0.01) by both Pam3CSK4 and LPS, but increased by RANKL, iii) the expression levels of TNFα and IL-6, inflammatory cytokines, were upregulated significantly (p<0.01) by both Pam3CSK4 and LPS and iv) the expression level of RANKL was similar to that of other experimental groups in RAW 264.7 cells (p>0.05). Collectively, these results indicate that Pam3CSK4, but not LPS, induces osteoclastogenesis in RAW 264.7 cells in the absence of exogenous RANKL.
No takes yet. Share an insight, caveat, or question.
Yano et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: